ProPhase Labs PRPH
OTC PRPH
$0.01 0.00 (-9.47%)
As of: Oct 23, 2026 · 11:54 AM EDT

ProPhase Labs (PRPH) Liabilities from Discontinued Operations (2023 - 2024)

Updated

ProPhase Labs (PRPH) reported Liabilities from Discontinued Operations of $2.92 million for Q4 2024, unchanged from $2.92 million a year earlier.

Analysis

ProPhase Labs (PRPH) Liabilities from Discontinued Operations (2023 - 2024) Analysis & Trends

  • By year, Liabilities from Discontinued Operations came in at $2.92 million in FY2023.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,137.66 Bn 1,106.24 Bn 19.71 Bn
2 Johnson & Johnson 636.13 Bn 556.00 Bn 17.30 Bn
3 AbbVie 505.28 Bn 478.39 Bn 12.70 Bn
4 Merck 358.10 Bn 312.48 Bn 12.21 Bn
5 Novartis Ag 292.59 Bn 256.58 Bn 11.24 Bn
6 Astrazeneca 265.81 Bn 239.50 Bn 12.86 Bn
7 Amgen 237.53 Bn 192.93 Bn 7.24 Bn
8 Gilead Sciences 194.67 Bn 168.86 Bn 6.22 Bn
9 Pfizer 171.17 Bn 117.82 Bn 10.94 Bn
10 ProPhase Labs 120,537.60 -425,462.40 226,000.00
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 2.92 Mn
Dec 31, 2023 2.92 Mn
API Access

ProPhase Labs Liabilities from Discontinued Operations API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=liabilities-from-discontinued-operations&ticker=PRPH&period=max&api_key=YOUR_API_KEY